SIRO Clinpharm, a global contract research organization (CRO) present in India, US, Europe and Israel, announced their alliance with Mediscis, an early drug development company based in Poitiers and La Rochelle, France. The pact will widen SIRO's reach in western Europe clinical research market.

Mediscis is an established expert in GCP compliant early phase drug development services including clinical trials and bioanalytics while SIRO offers expertise across all study phases for the pharmaceutical and biotech industry.

"This will be an important collaboration for both the parties as they stand to gain access to each others' core competencies," said Scott Spector, president, SIRO, Strategic Operations, Europe. "This alliance will allow us to provide additional services to our global clients to support their clinical development plans."

"Following the acquisition of Omega Mediation Clinical Research Services, SIRO was able to establish a footprint in the European clinical research market. We envision becoming a leading drug development solutions provider by delivering compelling value propositions to the global healthcare industry. From this alliance, we are glad that we can offer a larger bouquet of services to our global clientele and move closer to our vision," said Dr Chetan Tamhankar, chief operating officer of SIRO Clinpharm.

SIRO Clinpharm Private Limited (SIRO) is among one of the leading global Clinical Research Organizations (CROs), offering full scope services, conducting clinical trials in the Pharmaceutical, Biotechnology and Medical Devices sectors in compliance with International Standards. SIRO is one of the first CROs founded in India, which caters to the needs of pharmaceutical companies across the world. The company has offices in India, USA, Israel and in Europe at Germany, Romania, Estonia, Greece & Czech Republic.